These results provide insights into the pathogenic mechanisms of B cell IFNβ concerning the production of autoAbs, immune complexes, and renal disease tissue damage that can help guide future therapies that target type I IFN for the treatment of SLE. This evidence concerns the gene IFNB1 and systemic lupus erythematosus.